The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Growth was broad-based across segments
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Move strengthens footprint in Western India and expands multi-specialty care network
The company allocated €56 million to research and development for next-generation line solutions
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
In his new role, Karthik will lead human capital strategy and HR operations across these regions
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
Subscribe To Our Newsletter & Stay Updated
